New York, NY -- (SBWIRE) -- 12/24/2013 -- PennyStockChronicle covers the breadth of the markets, from NASDAQ, NYSE, AMEX, ETF, Penny Stocks, Emerging Markets, activities at the Fed and more. PennyStockChronicle brings you the most vibrant coverage of following stocks: Tower Group International, Ltd (NASDAQ:TWGP), OCZ Technology Group Inc (NASDAQ:OCZ), Galena Biopharma Inc (NASDAQ:GALE), CytRx Corporation (NASDAQ:CYTR)
Tower Group International, Ltd (NASDAQ:TWGP) showed a volume of 5.20 million shares by the end of last trade whereas the average volume of the stock remained 2.82 million shares. The stock opened the session at $2.67 but then moved to $2.89. At that price, the stock showed a positive performance of 9.06%.
Will TWGP Continue To Move Higher? Find Out Here
OCZ Technology Group Inc (NASDAQ:OCZ) opened the session at $0.07 and closed the session at $0.0632. The stock showed a negative performance of -6.51% in previous trading session. Traded with volume of 3.49 million shares in the prior session and the average volume of the stock remained 6.98 million shares. OCZ Technology Group, Inc. (OCZ) designs, manufactures, and distributes solid-state drives (SSDs) and computer components. OCZ designs and manufactures SSDs in a variety of form factors and interfaces including Serial advanced technology attachment (SATA), serial-attached small computer system interface (SAS), peripheral component interconnect express (PCIe), as well as the development of flash management software, caching and virtualization software. The Company is also a provider of flash controller silicon and firmware for SSDs. In addition to SSD technology,
Has OCZ Found The Bottom And Ready To Gain Momentum? Find Out Here
Galena Biopharma Inc (NASDAQ:GALE) opened the session at $4.05 and closed the session at $4.04. The stock showed a positive performance of 0.25% in previous trading session. Traded with volume of 2.55 million shares in the prior session and the average volume of the stock remained 6.57 million shares. The beta of the stock remained 1.10. Galena Biopharma, Inc. (Galena), formerly RXi Pharmaceuticals Corporation, is a biotechnology company focused on discovering, developing and commercializing therapies addressing unmet medical needs using targeted biotherapeutics. The Company is pursuing the development of cancer therapeutics using peptide-based immunotherapy products, including its main product candidate, NeuVaxTM (E75), for the treatment of breast cancer and other tumors.
Why Should Investors Buy GALE After The Recent Gain? Just Go Here and Find Out
CytRx Corporation (NASDAQ:CYTR) the stock decreased -6.22% and finished the session at $4.37. Traded with volume of 2.18 million shares in the prior session and the average volume of the stock remained 3.95 million shares. The beta of the stock remained 1.21. CytRx Corporation (CytRx) is a biopharmaceutical research and development company specializing in oncology. The Company's oncology pipeline includes three programs in clinical development for cancer indications: INNO-206, tamibarotene and bafetinib. INNO-206 is the Company's tumor-targeted doxorubicin conjugate. On May 13, 2011, the Company sold all pre-clinical and clinical data, intellectual property rights and other assets relating to those compounds to Orphazyme ApS. During the year ended December 31, 2011, the Company sold of its 19% interest in SynthRx to ADVENTRX Pharmaceuticals.
Will CYTR Get Buyers Even After The Recent Rally? Find Out Here
Penny Stock Chronicle is comprised of a team of vetted penny stock traders who’ve been trading since 2008 & have developed the skills needed to trade for consistent profits.
PLEASE NOTE WELL: The employees of PennyStockChronicle.com are not registered as Investment Advisors in any jurisdiction whatsoever. Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. Investing in “penny stocks” is highly speculative.
Verify all claims and do your own due diligence on all securities. PennyStockChronicle.com profiles are not a solicitation or recommendation to buy, sell or hold securities. PennyStockChronicle.com is not offering securities for sale. Neither PennyStockChronicle.com nor its owners, operators, affiliates or anyone disseminating information on its behalf is registered as an Investment Advisor under any federal or state law and none of the information provided by PennyStockChronicle.com, its owners, operators, affiliates or anyone disseminating information on its behalf should be construed as investment advice or investment recommendations. PennyStockChronicle.com does not recommend that the securities profiled should be purchased, sold or held.
Read Full Disclaimer at: http://pennystockchronicle.com/disclaimer
Copyright © 2005-2014 - SBWire, The Small Business Newswire - All Rights Reserved - Important Disclaimer
Contact Us: 888-4-SBWIRE (US) - 920-593-5640 (International)